RT Journal Article
SR Electronic
T1 Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.19.20038786
DO 10.1101/2020.03.19.20038786
A1 Hollis, Robert L
A1 Thomson, John P
A1 Stanley, Barbara
A1 Churchman, Michael
A1 Meynert, Alison M
A1 Rye, Tzyvia
A1 Bartos, Clare
A1 Iida, Yasushi
A1 Croy, Ian
A1 Mackean, Melanie
A1 Nussey, Fiona
A1 Okamoto, Aikou
A1 Semple, Colin A
A1 Gourley, Charlie
A1 Herrington, C. Simon
YR 2020
UL http://medrxiv.org/content/early/2020/03/24/2020.03.19.20038786.abstract
AB Endometrioid ovarian carcinoma (EnOC) is an under-investigated type of ovarian carcinoma. Here, we report the largest genomic study of EnOCs to date, performing whole exome sequencing of 112 cases following rigorous pathological assessment. High frequencies of mutation were detected in CTNNB1(43%), PIK3CA(43%), ARID1A(36%), PTEN(29%), TP53(26%) and SOX8(19%), a novel target of recurrent mutation in EnOC. POLE and mismatch repair protein-encoding genes were mutated at lower frequency (6%, 18%) with significant co-occurrence. A molecular taxonomy was constructed using a novel algorithm (PRISTINE), identifying clinically distinct EnOC subtypes: TP53m cases demonstrated greater genomic complexity, were frequently FIGO stage III/IV at diagnosis (48%) and incompletely debulked (44%), and demonstrated inferior survival; conversely, CTNNB1m cases demonstrated low complexity and excellent clinical outcome, were predominantly stage I/II at diagnosis (89%) and completely resected (87%). Tumour complexity provides further resolution within the TP53wt/CTNNB1wt group. Moreover, we identify the WNT, MAPK/RAS and PI3K pathways as good candidate targets for molecular therapeutics in EnOC.Competing Interest StatementMM: honoraria from Tesaro, BristolMyersSquibb and Roche. FN: non-personal interests in AstraZeneca and Tesaro. CG discloses: research funding from AstraZeneca, Aprea, Nucana, Tesaro and Novartis; honoraria/consultancy fees from Roche, AstraZeneca, MSD, Tesaro, Nucana, Clovis, Foundation One, Cor2Ed and Sierra Oncology; named on issued/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.Clinical TrialThe manuscript reports a retrospective study.Funding StatementRLH was supported by an MRC-funded Research Fellowship. BS was supported by the Oncology Endowment Fund (University of Edinburgh) and Edinburgh Lothian Health Fund. We extend our thanks to The Nicola Murray Foundation for their generous support of our laboratory. CAS and AMM are supported by core MRC funding to the MRC Human Genetics Unit.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to generate the analyses presented here are currently being submitted to the European Genome-phenome Archive (EGA) and once data upload completed will be made available upon request to our data access committee. For more information please see https://ega-archive.org/access/data-access